{"organizations": [], "uuid": "bb3595e6a2cc9354e8e6c8cb1cad53d0419014ca", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-roche-expands-indication-for-cobas/brief-roche-expands-indication-for-cobas-egfr-mutation-test-v2-as-companion-diagnostic-with-tagrisso-idUSFWN1RV10E", "country": "US", "domain_rank": 408, "title": "BRIEF-Roche Expands Indication For Cobas EGFR Mutation Test V2 As Companion Diagnostic With Tagrisso", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T02:22:00.000+03:00", "replies_count": 0, "uuid": "bb3595e6a2cc9354e8e6c8cb1cad53d0419014ca"}, "author": "", "url": "https://www.reuters.com/article/brief-roche-expands-indication-for-cobas/brief-roche-expands-indication-for-cobas-egfr-mutation-test-v2-as-companion-diagnostic-with-tagrisso-idUSFWN1RV10E", "ord_in_thread": 0, "title": "BRIEF-Roche Expands Indication For Cobas EGFR Mutation Test V2 As Companion Diagnostic With Tagrisso", "locations": [], "entities": {"persons": [{"name": "cobas egfr mut", "sentiment": "negative"}, {"name": "cobas", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "roche holding ag", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "cobas", "sentiment": "none"}, {"name": "astrazeneca", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 19 (Reuters) - Roche Holding AG:\n* ROCHE EXPANDS INDICATION FOR COBAS® EGFR MUTATION TEST V2 AS A COMPANION DIAGNOSTIC WITH TAGRISSO®\n* ROCHE HOLDING- NEW INDICATION AS COMPANION DIAGNOSTIC WITH ASTRAZENECA’S TAGRISSO IN FIRST LINE TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER\n* ROCHE -RECEIVED APPROVAL FROM FDA OF ITS PMA SUPPLEMENT FOR COBAS EGFR MUTATION TEST V2 TO BE USED AS COMPANION DIAGNOSTIC TEST WITH TAGRISSO Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-04-19T02:22:00.000+03:00", "crawled": "2018-04-19T02:41:07.004+03:00", "highlightTitle": ""}